针对TCR-T细胞的肿瘤特异性新抗原的筛选、鉴定、设计和临床应用。
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells.
发表日期：2023 Aug 30
作者：
Jiangping Li, Zhiwen Xiao, Donghui Wang, Lei Jia, Shihong Nie, Xingda Zeng, Wei Hu
来源：
Molecular Cancer
摘要：
近年来新抗原研究的进展加速了肿瘤免疫疗法的发展，包括细胞免疫治疗（ACTs）、癌症疫苗和抗体治疗，尤其是针对实体瘤。随着下一代测序和生物信息学技术的发展，快速鉴定和预测肿瘤特异性抗原（TSAs）已成为可能。与肿瘤相关抗原（TAAs）相比，高免疫原性的TSAs为个体化肿瘤免疫治疗提供了新的靶点，并可作为预测肿瘤患者生存、预后和免疫检查点阻断反应的前景指标。本文总结了新抗原的鉴定和表征，以及新抗原基于TCR-T免疫治疗策略的临床应用，并讨论了这些策略的现状、固有挑战和临床转化潜力。© 2023. BioMed Central Ltd., part of Springer Nature.
Recent advances in neoantigen research have accelerated the development of tumor immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody-based therapies, particularly for solid tumors. With the development of next-generation sequencing and bioinformatics technology, the rapid identification and prediction of tumor-specific antigens (TSAs) has become possible. Compared with tumor-associated antigens (TAAs), highly immunogenic TSAs provide new targets for personalized tumor immunotherapy and can be used as prospective indicators for predicting tumor patient survival, prognosis, and immune checkpoint blockade response. Here, the identification and characterization of neoantigens and the clinical application of neoantigen-based TCR-T immunotherapy strategies are summarized, and the current status, inherent challenges, and clinical translational potential of these strategies are discussed.© 2023. BioMed Central Ltd., part of Springer Nature.